| 1 |
27632988 | Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction. | 2017 |
1 |
| 2 |
27440861 | The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine. | 2016 Oct |
3 |
| 3 |
25719307 | Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. | 2015 Sep |
1 |
| 4 |
22764579 | Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10. | 2012 May |
2 |
| 5 |
28520379 | Imipramine Therapy and CYP2D6 and CYP2C19 Genotype | 2012 |
1 |
| 6 |
19884907 | The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. | 2010 Jun |
1 |
| 7 |
17667959 | Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. | 2008 Jun |
9 |
| 8 |
18310890 | Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. | 2008 Mar |
3 |
| 9 |
15687478 | QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. | 2005 Mar |
1 |
| 10 |
16141545 | Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. | 2005 Sep |
2 |
| 11 |
12695349 | Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. | 2003 May |
1 |
| 12 |
12065442 | Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. | 2002 Jul |
1 |
| 13 |
9205822 | Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. | 1997 Jun |
4 |
| 14 |
9256169 | Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. | 1997 Jun 15 |
2 |
| 15 |
9505989 | Olanzapine: interaction study with imipramine. | 1997 Oct |
1 |
| 16 |
9512923 | Synthetic strategies to lower affinity for CYP2D6. | 1997 Oct-Dec |
3 |
| 17 |
8835703 | Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. | 1996 Aug |
1 |
| 18 |
8521680 | Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. | 1995 Sep |
1 |
| 19 |
8310712 | Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. | 1993 Nov |
3 |
| 20 |
8335704 | Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability. | 1993 Jun 2 |
3 |